Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Cash: 2009-2025

Historic Change in Cash for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $152.0 million.

  • Cytokinetics' Change in Cash rose 206.12% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.3 million, marking a year-over-year increase of 443.38%. This contributed to the annual value of -$18.2 million for FY2024, which is 139.31% down from last year.
  • Per Cytokinetics' latest filing, its Change in Cash stood at $152.0 million for Q3 2025, which was up 5,990.87% from $2.5 million recorded in Q2 2025.
  • Cytokinetics' Change in Cash's 5-year high stood at $152.0 million during Q3 2025, with a 5-year trough of -$143.3 million in Q3 2024.
  • Moreover, its 3-year median value for Change in Cash was $13.3 million (2023), whereas its average is $14.7 million.
  • As far as peak fluctuations go, Cytokinetics' Change in Cash spiked by 1,207.47% in 2023, and later tumbled by 561.32% in 2024.
  • Cytokinetics' Change in Cash (Quarterly) stood at $22.1 million in 2021, then plummeted by 276.69% to -$39.1 million in 2022, then skyrocketed by 134.14% to $13.3 million in 2023, then surged by 259.80% to $48.0 million in 2024, then surged by 206.12% to $152.0 million in 2025.
  • Its Change in Cash stands at $152.0 million for Q3 2025, versus $2.5 million for Q2 2025 and -$21.2 million for Q1 2025.